Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Barth Syndrome Followed by an Open-Label Treatment Extension
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Elamipretide (Primary)
- Indications Barth syndrome
- Focus Registrational; Therapeutic Use
- Acronyms TAZPOWER
- Sponsors Stealth BioTherapeutics
- 08 Apr 2024 According to a Stealth BioTherapeutics media release, company announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for elamipretide for the treatment of Barth syndrome. The NDA is supported by the positive data from the SPIBA-001 Phase 3 Natural History Control Study and additional supporting efficacy and safety data from the TAZPOWER Part 2 baseline-controlled trial.
- 09 Mar 2023 Results presented in a Stealth BioTherapeutics media release.
- 09 Mar 2023 According to a Stealth BioTherapeutics media release, company will present data from week 168 at the 2023 American College of Medical Genetics Meeting, to be held March 14-18, 2023 in Salt Lake City, Utah.